孕母接种呼吸道合胞病毒融合糖蛋白疫苗对新生狒狒呼吸道合胞病毒肺部攻击的实质保护
全球范围内人呼吸道合胞病毒(RSV)是婴幼儿严重下呼吸道感染的主要病因,目前尚无获批疫苗。本研究在狒狒孕母免疫模型中评估RSV融合(F)糖蛋白疫苗的免疫原性与对子代肺部攻击的保护作用。孕晚期接种可诱导高滴度抗RSV F IgG和病毒中和抗体,子代出生时血清抗体水平与母体相当,持续超过50天,半衰期14-24天;免疫组子代攻击后健康、病情较轻、肺部炎症改变轻微,而未免疫组子代出现较重间质性肺炎、肺水肿和细支气管阻塞。
要点
- 孕晚期接种RSV F疫苗在狒狒中诱导高滴度抗RSV F IgG和中和抗体。
- 免疫组子代出生时抗体水平与母体相当,持续超过50天,半衰期14-24天。
- 免疫组子代RSV攻击后健康、病情较轻、肺部炎症轻微,未免疫组出现较重间质性肺炎、肺水肿和细支气管阻塞。
核心结论
- 结果支持进一步开发RSV F疫苗用于孕母免疫。
研究设计与样本
- 采用狒狒孕母免疫模型评估RSV F糖蛋白疫苗的免疫原性及子代对人RSV/A肺部攻击的保护作用。
主要发现
- 孕晚期接种产生高抗RSV F IgG滴度和病毒中和抗体。
- 免疫组子代出生时血清RSV抗体水平与母体相当,持续超过50天,半衰期14-24天。
- 免疫组子代攻击后健康、病情较轻、肺部炎症改变轻微;未免疫组子代出现较重病情伴显著至中度间质性肺炎、肺水肿和细支气管阻塞。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globally, human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infection in infants and young children. There are no licensed vaccines despite the high worldwide disease burden. RSV fusion (F) glycoprotein vaccine is the most advanced candidate for maternal immunization. In this report, a baboon maternal immunization model was used to assess the immunogenicity and protection of infants against pulmonary challenge with human RSV/A. Vaccination in the third trimester produced high anti-RSV F IgG titers and virus-neutralizing antibodies. Infants born to immunized females had high levels of serum RSV antibodies that were comparable to maternal levels at birth and persisted for over 50 days with a half-life of 14-24 days. Furthermore, infants from immunized females and challenged with RSV/A were healthy, developed less severe disease, and had only mild pulmonary inflammatory changes whereas infants born to non-vaccinated females developed more severe disease with marked to moderate interstitial pneumonia, pulmonary edema, and bronchiolar obstruction. These results support the further development of the RSV F vaccine for maternal immunization.
引用
- Welliver RC, Papin JF, Preno A, et al. Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge. Vaccine. 2019. PMID: 31761502. doi:10.1016/j.vaccine.2019.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。